This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Investigators explore new frontiers in the development of tomorrow's pain medicines

May 25th, 2011

Prodigious progress has been made in the last decade toward a deeper understanding and improved treatment of chronic pain. Yet, identifying novel mechanisms that underlie this complex array of conditions and developing innovative therapies to tackle them remains challenging. On June 2-3, 2011, leading and emerging investigators studying the pathophysiological mechanisms underlying neuropathic and chronic pain and experts in the clinical development of pain therapies will convene at the New York Academy of Sciences to address novel issues, current challenges and future directions of basic research in pain and pre-clinical and clinical development of new therapies for chronic pain.

"Neurological conditions such as chronic pain represent a significant burden for patients and society. In fact, one in three people will suffer chronic pain at some point in their lives," said Dr. Marta Murcia of the New York Academy of Sciences. "New research in this field is particularly important, and providing a forum to present and discuss these emerging discoveries supports our mission to advance scientific research and knowledge."

The one-and-a-half-day conference, presented by The New York Academy of Sciences, MedImmune and Grünenthal Gmbh, features plenary lectures by prominent contributors to this field and a keynote address by Dr. Clifford J. Woolf. Presentations will examine: (i) recent therapeutic breakthroughs based on small molecules; (ii) the emerging role of biologics as potential new therapies; and (iii) current challenges and potential solutions for improved translation of new pain therapies following early target identification, pre-clinical modeling and clinical development.

WHAT: A Scientific Symposium on Chronic Inflammatory and Neuropathic Pain

WHO:

Iain Chessell, PhD, MedImmune

Thomas Christoph, PhD, Grünenthal GmbH

Mark J. Field, PhD, Grünenthal GmbH

Jane Hughes, PhD, MedImmune

Richard Malamut, MD, AstraZeneca

Martin Perkins, PhD, AstraZeneca

Nora Sjödin, AstraZeneca

Brooke Grindlinger, PhD, The New York Academy of Sciences

Marta Murcia, PhD, The New York Academy of Sciences

WHEN:
Thursday, June 2, 2011 - Friday, June 3, 2011

WHERE:

The New York Academy of Sciences

7 World Trade Center

250 Greenwich Street, 40th floor

New York, NY 10007-2157

212.298.8600

More information:
www.nyas.org/neuropathicpain

Provided by New York Academy of Sciences

Citation: Investigators explore new frontiers in the development of tomorrow's pain medicines (2011, May 25) retrieved 12 August 2026 from https://sciencex.com/wire-news/67776970/investigators-explore-new-frontiers-in-the-development-of-tomorr.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.